/Bill Kelly

About Bill Kelly

This author has not yet filled in any details.
So far Bill Kelly has created 1309 blog entries.

Yale team ‘reengineers’ immune cells

Yale researchers have developed a new way to efficiently engineer immune cells, an advance which enhances the ability to fend off cancer and other diseases. A Yale team headed by Sidi Chen, assistant professor of genetics and in the Systems Biology Institute, utilize a system that relies on the cell’s own repair machinery to integrate new genes into its genome. They used a single protein capable of snipping sections of the genome at multiple points and a repurposed virus to introduce modified genes at specific locations. more

By |March 17th, 2019|News|0 Comments

Biohaven receives orphan status for MSA drug

Biohaven Pharmaceutical Holding Company has received orphan drug designation from the FDA for its product candidate verdiperstat (previously BHV-3241), a novel myeloperoxidase inhibitor, for the treatment of multiple system atrophy (MSA). Irfan Qureshi, M.D., Biohaven Executive Director and development lead for verdiperstat, commented, "We believe verdiperstat has the potential to be the first effective treatment for people living with MSA and we remain on track to start our global Phase 3 clinical trial later this year." more

By |March 17th, 2019|News|0 Comments

BioCT welcomes Megan Rosengarten to Board

BioCT is pleased to welcome Megan Rosengarten to the BioCT Board of Directors. Megan is a proven leader known for commercializing new insights and opportunities, resulting in sustainable growth and iconic brands. She rejoined Medtronic in January 2018 as the Vice President and General Manager for Surgical Innovations’ Surgical Robotics business. [biography] Anthony Sabatelli and Larry Weiss have stepped down from the Board. Anthony remains on BioCT's Government Affairs Committee. BioCT thanks Anthony and Larry for their service and the valuable contributions they have made during their tenure as directors.

By |March 17th, 2019|News|0 Comments

InveniAI® Corporation featured in Guardian article

InveniAI® Corporation, a Guilford-based global leader in pioneering the application of artificial intelligence and machine learning to transform innovation across healthcare and other industries, was featured in a recent article in The Guardian. InveniAI has leveraged its AlphaMeldTM platform for numerous collaborations such as Alexion, Axcella Health, Centrexion, and most recently Kyowa Hakko Kirin. "We believe that our artificial intelligence and machine learning platform can make a significant impact in helping our partners create breakthrough treatments with a high probability of success,” said Krishnan Nandabalan, Ph.D., CEO and President. more

By |March 17th, 2019|News|0 Comments

Vanessa Research paper on microvillus inclusion disease

Vanessa Research reports the publication of a new white paper, the first and only comprehensive case analysis that focuses on all known case studies published globally on microvillus inclusion disease (MVID). MVID is an exceedingly rare genetic gastrointestinal disorder that afflicts infants with diarrhea so severe that malnutrition and dehydration are inevitable, and often lethal if the condition is not appropriately diagnosed and treated. more

By |March 17th, 2019|News|0 Comments

PAREXEL announces appointments re oncology

PAREXEL International has announced several new appointments that will enhance the company’s oncology expertise as oncology trials grow in number and complexity. Amy McKee, M.D., former Deputy Director of the FDA's Oncology Center of Excellence, will be focused on building the Company’s new cross-functional Oncology initiative. Also joining the company is Dr. Matthew Cooney, M.D., a Medical Oncologist most recently with University Hospitals in Cleveland, as Senior Medical Director and Therapeutic Area Lead for Oncology within PAREXEL’s Global Medical Services team. more

By |March 17th, 2019|News|0 Comments

University of New Haven pursues patient-centered care

The University of New Haven’s School of Health Sciences has signed a letter of intent to become one of first schools in the United States to pursue higher education certification from Planetree International, a leading nonprofit that works with organizations around the world to promote patient-centered care as a model for improving the quality of healthcare. “It is a critical component of the School of Health Sciences’ mission to incorporate person-centered care into health sciences education,” said Summer McGee, Ph.D., Dean of the University’s School of Health Sciences. more

By |March 17th, 2019|News|0 Comments

Connecticut Bioscience Pipeline applications due

The Connecticut Bioscience Pipeline program, a partnership between Connecticut Innovations, the University of Connecticut, Quinnipiac University and Yale University, has launched the first of four open application periods in search of new ideas that can one day become investable business ventures in the medical devices, drug delivery, diagnotics and health IT industries. Eligible projects can qualify for up to $30,000 per team over 12 months to be used for business strategy, market definition and prototyping, and proof-of-concept activities. Applications for this first round must be submitted by 5:00 p.m. ET on April 26 more

By |March 17th, 2019|News|0 Comments

BioCT welcomes new member Sophia Consulting

The mission of The Sophia Consulting Firm is to help emerging and established healthcare companies articulate their clinical and economic value through strategic communications: public relations, investor relations, scientific and medical communications, publication planning and congress support. Capabilities Overview BioCT Directory Listing

By |March 17th, 2019|News|0 Comments

UConn chemist researches urinary tract infections

Researchers working on developing a more effective treatment for infections would benefit greatly from being able to study exactly how a pathogen infects the body. UConn chemistry professor Mark Peczuh specializes in making this possible. Peczuh recently received $275,000 from the National Institute of Allergy and Infectious Diseases to develop a molecule used to study an alternative approach to preventative treatments for urinary tract infections (UTI). more

By |March 17th, 2019|News|0 Comments